We are proud to share that the Weill Cornell Medicine Genetics and Personalized Cancer Prevention (GPCP) Program and our Director, Dr. Melissa Frey, were recently featured in the October Sports Illustrated Swimsuit article, This Breast Cancer Survivor Is Advocating for Equitable Care and Advanced Screenings.
The piece spotlights one of our inspiring GPCP patients whose advocacy is helping to transform how we think about genetic testing and integrating hereditary cancer testing into IVF and preconception genetic screening. Historically, cancer-predisposition genes have not been included in preconception testing, representing a missed opportunity to identify individuals at elevated cancer risk early - when enhanced screening and preventive care can make the greatest impact.
Dr. Frey shared how this advocacy helped spark a groundbreaking new clinical trial at Weill Cornell Medicine — the FOCUS study (Feasibility of Obstetric and Cancer Universal Screening). The trial offers individuals the option to include hereditary cancer screening alongside traditional carrier testing for obstetric conditions.
“Our goal is to ensure that everyone has access to the knowledge and tools to make informed, proactive choices about their health,” said Dr. Frey. “By expanding genetic testing options, we can help prevent cancers before they start.”
At GPCP, we remain deeply committed to advancing early cancer prevention and personalized risk assessment.
If you’re interested in learning more about your personalized cancer risk or exploring preventive options, we welcome you to connect with our team.
Schedule a visit: (646) 962-5100
Read the full Sports Illustrated Swimsuit article here: This Breast Cancer Survivor Is Advocating for Equitable Care and Advanced Screenings
